Orthocell (ASX:OCC) shares fall despite US patent for CelGro®

Summary

  • World-leading regenerative medicine player Orthocell Limited has obtained US patent for CelGro®.
  • The patent also complements market authorisation of Striate+, the first CelGro® product.
  • CelGro® offers its benefits in the field of cell biocompatibility, the promotion of high-quality tissue repair, and tensile strength.

ASX-listed regenerative medicine player Orthocell Limited (ASX:OCC) updated the market that the Company has obtained a new US divisional patent for its technology platform, CelGro®.  The patent covers the manufacturing method of collagen medical devices and as an aid for surgical repairing of soft tissue injuries.

Despite the positive news, OCC shares ended the day’s session in red at A$0.550, falling 1.786%. The Company has a market capitalisation of A$105.70 million.

Let us delve deeper and shed some light on the new patent-

Orthocell obtains US divisional patent for CelGro®

On 15 February 2021, Orthocell updated the market that the Company has obtained US patent entitled “Method for Producing a Collagen Membrane and Uses Thereof” for CelGro®.

The patent offers additional important IP (intellectual property) for protecting the CelGro® platform for soft tissue regeneration and repair applications. The patent will expire in June 2033.

Source: OCC Investor Presentation (September 2020)

Managing Director of Orthocell Paul Anderson commented-

Orthocell’s Strong IP Portfolio

Orthocell has obtained 11 patent families covering the Company’s portfolio of breakthrough regenerative medicine products. These patent families include 110 separate patents or patent applications, of which seventy-five are granted.

CelGro® is a customisable collagen medical device manufactured by Orthocell at its quality-controlled facility in Western Australia, using proprietary tissue engineering process, SMRTTM.

Moreover, CelGro® patents have been granted in Australia, Canada, China, Europe, Japan, New Zealand, Singapore, and the US.

The Company is confident that CelGro® has several competitive advantages compared to the existing synthetic as well as biologic tissue repair devices.

CelGro® offers its benefits particularly in the field of cell biocompatibility, the promotion of high-quality tissue repair, and tensile strength.

Source: OCC Investor Presentation (September 2020)

CelGro® has demonstrated high-quality outcomes for-

  • Bone defects repairment in the jaw.
  • Assisting the re-joining of damaged or severed peripheral nerves.
  • Augmenting repair of the rotator cuff tendon within shoulder.

Striate+ in a nutshell

CelGro® dental, recently named Striate+, is the first product having CelGro® platform technology to gain approval in Australia, Europe, and the US.

Based on the feedback from surgeons, Striate+ has distinct advantages as compared to other similar products.  Striate+ may assist surgeons in delivering improved patient results via improved bone healing, superior handling characteristics, and tissue integration qualities.

With significant market authorisations and key opinion leaders keenly participating in the program, Orthocell is well placed to obtain a distribution partner. Notably, the Company to develop Striate+ as the best-in-class resorbable collagen membrane for dental use.

ALSO READ: Orthocell (ASX:OCC) Share Riding High on Positive Results from Nerve Repair Trial

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK